Acumen Pharmaceuticals, Inc. — Q3 2021 Form 10-Q
Reporting period: Unaudited quarter and nine months ended September 30, 2021. Acumen is a clinical-stage biotechnology company developing ACU193, an antibody targeting amyloid-beta oligomers for Alzheimer’s disease. It had no approved products and generated no product-sale revenue.
Financial highlights
- Revenue: None in the quarter or nine-month period. NIH grant revenue was $0.7 million in Q3 2020 and $1.1 million in the first nine months of 2020; the grant was fully recognized by the end of 2020.
- Operating expenses: Q3 expenses were $3.9 million, versus $3.2 million a year earlier. Nine-month expenses were $11.2 million, versus $7.7 million. Nine-month R&D was $6.6 million; G&A was $4.5 million.
- Net loss: Q3 loss was $3.9 million, compared with $2.5 million in Q3 2020. Nine-month loss was $92.3 million, versus $6.6 million in the prior-year period. The 2021 nine-month loss includes $81.2 million of noncash expense from fair-value changes in preferred-stock tranche and warrant liabilities, which were settled or reclassified during the year.
- Cash flow: Nine-month operating cash use was $14.3 million; investing cash use was $94.1 million, primarily purchases of marketable securities; financing provided $200.5 million. Cash and cash equivalents increased by $92.0 million.
- Liquidity and debt: At September 30, cash and cash equivalents were $135.8 million and marketable securities totaled $94.1 million. Working capital was $203.4 million. Total liabilities were $1.5 million, consisting principally of accounts payable and accrued liabilities; the filing reports no material debt.
- Margins: Not meaningful because the company had no product revenue. Accumulated deficit was $119.2 million.
Material changes versus comparable periods
- Q3 G&A increased to $2.1 million from $0.2 million, largely reflecting public-company costs, insurance and personnel; R&D declined to $1.8 million from $3.0 million as preclinical activity decreased.
- For the first nine months, G&A rose to $4.5 million from $0.7 million, while R&D edged down to $6.6 million from $7.0 million. The company attributed the R&D decrease to lower preclinical spending, partly offset by clinical-trial costs.
- The July 2021 IPO generated $168.6 million in net proceeds. Preferred stock converted into common stock at the IPO; 40.5 million common shares were outstanding at September 30.
Outlook, risks and unusual items
- Management estimated that cash, cash equivalents and marketable securities would fund operating and capital requirements at least through 2024, based on its current plan and assumptions. It expects losses and expenses to increase as ACU193 development and public-company operations expand; additional financing may be needed.
- INTERCEPT-AD is a placebo-controlled Phase 1 study planned for approximately 62 people with early Alzheimer’s disease, assessing safety, tolerability, pharmacokinetics and target engagement. The first patient was dosed in October 2021 and the trial cleared its sentinel safety review. Recruitment and site activation were ongoing; topline data were anticipated by the end of 2022, subject to enrollment and site-activation progress.
- COVID-19, particularly the Delta variant, delayed site activation and enrollment. The company said slower recruitment could affect the trial timeline.
- ACU193 is the company’s sole product candidate, and its safety and efficacy in humans had not yet been established. Development, regulatory, manufacturing, competition, intellectual-property and future-funding risks remain substantial.
- Disclosure controls were deemed ineffective as of September 30 because of an unremediated material weakness in accounting segregation of duties and review controls. The company reported no resulting financial-statement misstatement; it hired a corporate controller in Q4 and planned further remediation.
- The company reported no material legal proceedings and no material off-balance-sheet arrangements. Its remaining lease obligations were approximately $0.3 million through August 2023.
Important facts for investors to verify
- Whether trial enrollment and site activation support the end-2022 topline-data target, and whether COVID-19 or other factors cause further delay.
- Whether the cash-runway estimate through 2024 remains valid as clinical and public-company costs rise.
- How ACU193 performs on safety, tolerability and target engagement; the Phase 1 study is not proof of clinical benefit.
- Progress and testing of controls to remediate the material weakness, including whether controls become effective.
- Potential share dilution from equity awards, future financing or other capital needs; assess the IPO-related share expansion and outstanding options.